Oxytocin
Bonding & connection — vial, cartridge or nasal spray
2mg700.000 ₫
Oxytocin is a nine-amino-acid neuropeptide produced by the hypothalamus, central to social bonding, trust, emotional regulation and reproductive behaviour. It modulates amygdala reactivity, dampens the cortisol/stress response and increases warmth and connection signals in social contexts. Researched outcomes include reduced social anxiety, improved partner-bonding and empathy, and dampened stress-axis reactivity. Of interest in PMDD-style luteal-phase symptoms, post-partum mood, attachment-driven anxiety and stress-resilience protocols. The Luna stack uses oxytocin combined with Selank (Calm) and Semax (Lift) in nasal-spray form. Available as 2mg vials for direct SubQ dosing, as a cartridge (+30%, includes disposable pen and needles), or as a pre-mixed nasal spray (+30%). Typically dosed as needed or in short cycles around stress / luteal phase.
Dosage
Typical research dose ~24 IU (≈48 µg) intranasal once daily during luteal phase.
Duration of effect
Effects on bonding and calm felt for 1-2 hours per dose (plasma half-life: ~3-5 minutes)
See full half-life table →Key Features
- Bonding & social connection
- Emotional regulation
- 2mg — vial, cartridge or spray
- Luteal phase protocol
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Translational Psychiatry (Nature), 2019 — Randomized Controlled Trial
Clinical Research
In a randomized controlled trial, intranasal oxytocin significantly enhanced empathy and approach motivation in human participants, demonstrating measurable improvements in social cognition and emotional regulation.
Read full studyAdditional Research
Source: Woolley et al., Schizophrenia Research (2014)
Randomised placebo-controlled trial in patients with schizophrenia: intranasal oxytocin enhanced controlled social cognition tasks — particularly emotion recognition and theory-of-mind — demonstrating measurable pro-social effects in a clinical human population.
Read full studyHuman Clinical Trials
- Intranasal oxytocin in autismNew England Journal of Medicine · 2021
24-week trial in 290 children and adolescents: no significant benefit over placebo on the main social outcome.
A negative result — included for balance.
Read the trial290participants